Babesia microti (B. microti) is an intra erythrocytic protozoan that mainly infects red blood cells and causes babesiosis. Its frequent hosts are rodents, ticks and humans. Dog's blood samples (N = 150) were collected from three different districts in Punjab including Multan (N = 49), Islamabad/Rawalpindi (N = 49) and Lahore (N = 52) while 159 cat's blood samples were collected from Lahore (N = 159). Data on the epidemiological characters of all animals (including age, gender, breed, body temperature, deworming, vaccination, mucus membrane status, hydration status, presence of hematuria and tick infestation) was collected through questionnaire. Polymerase chain reaction (PCR) amplified a 238 base pair amplicon specific for 18S rRNA gene of B. microti in two (1.3%) dog and 21 (13.2%) cat blood samples. Amplified PCR products were confirmed by DNA sequencing and the four partial 18S rRNA gene sequences were submitted to the EMBL/GenBank. Among epidemiological factors, high body temperature (P < 0.05) and pale mucous membrane (P < 0.05) were the parameters associated with the presence of B. microti in infected dogs. Females were found to be more infected (P = 0.05) than males and incidence of B. microti infection was higher in cat samples collected during winter months (P = 0.0001) than in summer. In conclusion, we are reporting the prevalence of B. microti in blood samples of cats and dogs from Pakistan for the first time and recommending that this Protozoan parasite should be considered for screening in cats and dogs with compatible clinical signs.
Download full-text PDF |
Source |
---|
Alzheimers Dement
December 2024
Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.
Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.
Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.
Background: Abnormal glucose metabolism in AD brains correlates with cognitive deficits. The glucose changes are consistent with brain thiamine (vitamin B1) deficiency. In animals, thiamine deficiency causes multiple AD-like changes including memory loss, neuron loss, brain inflammation, enhanced phosphorylation of tau, exaggerated plaque formation and elevated advanced glycation end products (AGE).
View Article and Find Full Text PDFBackground: Previously, we demonstrated therapeutic benefits following intraperitoneal delivery of the TGR5 agonist HY209 in 5xFAD, a transgenic mouse model of Alzheimer's Disease (AD). Given the desirability of a more acceptable administration route for prolonged AD treatment, we assessed the efficacy of HY209 via oral delivery. This study aims to elucidate the therapeutic potential of NuCerin, an oral formulation of HY209, in the aforementioned AD model, while simultaneously identifying potential blood biomarkers indicative of NuCerin's therapeutic action.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: Blood pressure (BP) management is an accessible therapeutic target for dementia prevention. BP variability (BPV) is a newer aspect of BP control recently associated with cognitive decline, dementia and Alzheimer's disease (AD), independent of traditionally targeted mean BP levels. Most of this work has relied on largely non-Hispanic White study samples in observational cohorts.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, USA.
Background: Benfotiamine, a prodrug of thiamine, raises blood levels by 50-100 times to achieve pharmacologic effects. It provides a novel therapeutic direction addressing a well-characterized brain tissue thiamine deficiency and related changes in glucose metabolism in AD. BenfoTeam is a seamless phase 2A-2B "proof of concept" (POC), double-blind, placebo-controlled RCT investigating tolerability, safety, and efficacy of benfotiamine, as a first-in-class small molecule treatment for early AD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!